glp-1 without diabetes use tripled among non-diabetics, reaching $5.8B in 2022 The expanding scope of GLP-1

Rev Physiol Biochem Pharmacol (2015) 169:4369

On GLP-1 therapy, these extras counteract your progress

In PIONEER-2, oral semaglutide reduced CRP, whereas empagliflozin did not, despite similar weight loss

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the exenatide study of cardiovascular event Lowering (EXSCEL)

There is no confirmed evidence that retatrutide causes thyroid cancer in humans

a Indications that may warrant additional assessment and/or laboratory testing prior to therapy: Prior history of a very low-calorie diet, bariatric surgery, celiac disease, other inflammatory conditions predisposing to nutrient deficiency